1 of 1
Story summary
- The U.S. FDA approved Mirum Pharmaceuticals’ oral drug Atebrioz for fibrodysplasia ossificans progressiva.
- Atebrioz (zilurgisertib) is approved for patients aged 12 years and older.
- The 63-patient PROGRESS trial showed a 3.2 cm³ reduction in new bone versus 24.6 cm³ with placebo.
- Atebrioz cut new-lesion incidence to 3.1% compared with 16.7% on placebo.
- Analysts project an annual price of about $750,000 and peak worldwide sales near $150 million.